Capmatinib (Tabrecta)

Targeted TherapyApproved for: NSCLCBiomarker: MET Capmatinib (Tabrecta) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has a certain mutation in the MET gene. It is used in adults whose disease has metastasized. Related Research News Study...
|
May 27, 2021
|